MedTrace Logo

Intracavernous Injection of Botox 100 U for Treatment of PDE5Is Inconvenient Patients With ED

NCT04172558 · Status: UNKNOWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 124

Last updated 2022-07-19

No results posted yet for this study

Summary

There is a new emerging concept that Botulinum Toxin Type A may have a potential role in treatment of erectile dysfunction with a longer duration of action. So, the investigators opted to perform this study to compare ICI of Botulinum Toxin Type A versus Trimix for treatment of ED.

Conditions

Interventions

BIOLOGICAL

OnabotulinumtoxinA

a single ICI of BTX-A 100 units one day after the penile Doppler/trimix test.

DRUG

Trimix

on demand ICI of Trimix

Sponsors & Collaborators

  • Benha University

    lead OTHER

Principal Investigators

  • Waleed El-Shaer, MD · Banha Univesity hosptals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
40 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-03-10
Primary Completion
2022-10-01
Completion
2022-11-01

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04172558 on ClinicalTrials.gov